190 related articles for article (PubMed ID: 20847179)
1. Added value of baseline 18F-FDG uptake in serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic neoadjuvant treatment: a meta-analysis.
Quarles van Ufford HM; van Tinteren H; Stroobants SG; Riphagen II; Hoekstra OS
J Nucl Med; 2010 Oct; 51(10):1507-16. PubMed ID: 20847179
[TBL] [Abstract][Full Text] [Related]
2. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
[TBL] [Abstract][Full Text] [Related]
3. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
[TBL] [Abstract][Full Text] [Related]
4. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
[TBL] [Abstract][Full Text] [Related]
5. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
[TBL] [Abstract][Full Text] [Related]
7. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
[TBL] [Abstract][Full Text] [Related]
8. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.
Yamane T; Daimaru O; Ito S; Yoshiya K; Nagata T; Ito S; Uchida H
J Nucl Med; 2004 Nov; 45(11):1838-42. PubMed ID: 15534052
[TBL] [Abstract][Full Text] [Related]
9. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
[TBL] [Abstract][Full Text] [Related]
10. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
11. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.
de Langen AJ; Vincent A; Velasquez LM; van Tinteren H; Boellaard R; Shankar LK; Boers M; Smit EF; Stroobants S; Weber WA; Hoekstra OS
J Nucl Med; 2012 May; 53(5):701-8. PubMed ID: 22496583
[TBL] [Abstract][Full Text] [Related]
12. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
14. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET.
Stahl A; Ott K; Schwaiger M; Weber WA
Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1471-8. PubMed ID: 15257418
[TBL] [Abstract][Full Text] [Related]
16. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.
Wang Y; Zhang C; Liu J; Huang G
Breast Cancer Res Treat; 2012 Jan; 131(2):357-69. PubMed ID: 21960111
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
18. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.
de Geus-Oei LF; van der Heijden HF; Visser EP; Hermsen R; van Hoorn BA; Timmer-Bonte JN; Willemsen AT; Pruim J; Corstens FH; Krabbe PF; Oyen WJ
J Nucl Med; 2007 Oct; 48(10):1592-8. PubMed ID: 17873138
[TBL] [Abstract][Full Text] [Related]
20. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
